Copyright
©The Author(s) 2024.
World J Psychiatry. May 19, 2024; 14(5): 644-652
Published online May 19, 2024. doi: 10.5498/wjp.v14.i5.644
Published online May 19, 2024. doi: 10.5498/wjp.v14.i5.644
Table 1 General data, n (%)
| Factors | Observation group (n = 65) | Control group (n = 59) | χ2 | P value |
| Sex | 0.002 | 0.065 | ||
| Male | 35 (53.85) | 32 (54.24) | ||
| Female | 30 (46.15) | 27 (45.76) | ||
| Age (yr) | 0.026 | 0.871 | ||
| ≤ 65 | 31 (47.69) | 29 (49.15) | ||
| > 65 | 34 (52.31) | 30 (50.85) | ||
| BMI (kg/m2) | 0.039 | 0.844 | ||
| ≤ 23 | 32 (49.23) | 28 (47.46) | ||
| > 23 | 33 (50.77) | 31 (52.54) | ||
| History of smoking | 0.009 | 0.923 | ||
| Yes | 38 (58.46) | 35 (59.32) | ||
| No | 27 (41.54) | 24 (40.68) | ||
| Diabetes | 0.009 | 0.993 | ||
| Yes | 32 (49.23) | 29 (49.15) | ||
| No | 33 (50.77) | 30 (50.85) | ||
| Hypertension | 0.084 | 0.772 | ||
| Yes | 38 (58.46) | 36 (61.02) | ||
| No | 27 (41.54) | 23 (38.98) | ||
| Drinking habit | 0.001 | 0.981 | ||
| Yes | 42 (64.62) | 38 (64.41) | ||
| No | 23 (35.38) | 21 (35.59) |
Table 2 Comparison of therapeutic efficacy, n (%)
| Curative effect | Observation group (n = 65) | Control group (n = 59) | χ2 | P value |
| Markedly effective | 38 (58.46) | 25 (42.37) | - | - |
| Effective | 24 (36.92) | 21 (35.59) | - | - |
| Ineffective | 3 (4.62) | 13 (22.03) | - | - |
| Effectiveness of treatment | 62 (95.38) | 46 (77.97) | 8.350 | 0.004 |
Table 3 Comparison of neurological deficit scores
| Time | Observation group (n = 65) | Control group (n = 59) | t | P value |
| Before treatment | 22.18 ± 1.01 | 22.24 ± 1.13 | 0.312 | 0.755 |
| After treatment | 11.25 ± 1.05 | 17.00 ± 1.10 | 29.772 | < 0.001 |
Table 4 Comparison of daily living ability
| Time | Observation group (n = 65) | Control group (n = 59) | t | P value |
| Before treatment | 52.34 ± 1.53 | 52.42 ± 1.80 | 0.267 | 0.790 |
| After treatment | 67.20 ± 1.54 | 59.37 ± 1.68 | 27.079 | < 0.001 |
Table 5 Comparison of cognitive function
| Time | Observation group (n = 65) | Control group (n = 59) | t | P value |
| Before treatment | 21.06 ± 1.07 | 21.15 ± 1.22 | 0.438 | 0.663 |
| After treatment | 24.94 ± 1.09 | 23.20 ± 1.00 | 9.232 | < 0.001 |
Table 6 Comparison of adverse reactions during medication, n (%)
| Adverse reactions | Observation group (n = 65) | Control group (n = 59) | χ2 | P value |
| Skin ecchymosis | 2 (3.08) | 1 (1.69) | - | - |
| Black stool | 2 (3.08) | 2 (3.39) | - | - |
| Dizziness | 3 (4.62) | 1 (1.69) | - | - |
| Stomach bleeding | 2 (3.08) | 1 (1.69) | - | - |
| Total incidence | 9 (13.85) | 5 (8.47) | 0.891 | 0.345 |
Table 7 Comparison of the quality of life after treatment
| Quality of life | Observation group (n = 65) | Control group (n = 59) | t | P value |
| Body function | 62.28 ± 1.39 | 49.49 ± 1.60 | 47.625 | < 0.001 |
| Social function | 65.09 ± 1.44 | 51.07 ± 1.57 | 51.868 | < 0.001 |
| Physiological state | 63.25 ± 1.35 | 52.00 ± 1.13 | 50.041 | < 0.001 |
| Mental state | 65.09 ± 1.38 | 53.19 ± 1.33 | 48.788 | < 0.001 |
- Citation: Wang TS, Jing LJ. Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction. World J Psychiatry 2024; 14(5): 644-652
- URL: https://www.wjgnet.com/2220-3206/full/v14/i5/644.htm
- DOI: https://dx.doi.org/10.5498/wjp.v14.i5.644
